June 2021 Simoa® Publications: Multiple Sclerosis, TBI, and Parkinson’s Disease
Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment
Devi-Marulkar P, et al.
Frontiers in immunology. 2021;12:628375
Multiple Sclerosis
Serum neurofilament light is a sensitive biomarker that reflects grey matter volume in Japanese patients with multiple sclerosis
Fujimori J and Nakashima I
Journal of the neurological sciences. 2021;427:117528
Multiple Sclerosis
Chronic White Matter Inflammation and Serum Neurofilament Levels in Multiple Sclerosis
Maggi P, et al.
Neurology. 2021
Multiple Sclerosis
Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis
Oechtering J, et al.
Ann Neurol. 2021 May 31
Multiple Sclerosis
Associations between neurofilament light chain levels, disease activity and brain atrophy in progressive multiple sclerosis
Szilasiova J, et al.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021 Jun 1
Multiple Sclerosis
Serum neurofilament light chain levels in healthy individuals: a proposal of cut-off values for use in multiple sclerosis clinical practice
Valentino P, et al.
Multiple sclerosis and related disorders. 2021:103090
Multiple Sclerosis
Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients
Youssef P, et al.
Journal of Parkinson’s disease. 2021
Parkinson’s Disease
Exposure to Repetitive Head Impacts Is Associated With Corpus Callosum Microstructure and Plasma Total Tau in Former Professional American Football Players
Kochsiek J, et al.
J Magn Reson Imaging. 2021
TBI
Traumatic brain injury biomarkers in pediatric patients: a systematic review
Marzano LAS, et al.
Neurosurg Rev. 2021
TBI
June 2021 Simoa® Publications in Other Therapeutic Areas
